# Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

> **NCT02583477** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 23 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** MEDI4736 in combination with nab-paclitaxel and gemcitabine
- **DRUG:** MEDI4736 in combination with AZD5069

## Key facts

- **NCT ID:** NCT02583477
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-25
- **Primary completion:** 2018-07-09
- **Final completion:** 2018-07-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583477, "Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02583477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*